The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir

被引:178
|
作者
Kempf, DJ
Rode, RA
Xu, Y
Sun, E
Heath-Chiozzi, ME
Valdes, J
Japour, AJ
Danner, S
Boucher, C
Molla, A
Leonard, JM
机构
[1] Abbott Labs, Antiviral Venture, Div Pharmaceut Prod, Abbott Pk, IL 60064 USA
[2] Abbott Labs, Dept Biostat, Abbott Pk, IL 60064 USA
[3] Abbott Labs, Dept Infect Dis Res, Abbott Pk, IL 60064 USA
[4] Univ Amsterdam, Acad Med Ctr, Div Infect Dis Trop Med & AIDS, NL-1105 AZ Amsterdam, Netherlands
[5] Univ Utrecht, Univ Hosp, Eijkman Winkler Inst Med & Clin MIcrobiol, Utrecht, Netherlands
关键词
viral load; durability of response; protease inhibitor; resistance;
D O I
10.1097/00002030-199805000-00001
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective: To determine markers that are associated with the durability of virologic response to therapy with HIV protease inhibitors in HIV-infected individuals. Design: This study encompassed two retrospective analyses of the duration of virologic response to protease inhibitor therapy. The first analysis included 29 patients receiving either monotherapy or combination therapy with the protease inhibitor ritonavir whose plasma HIV RNA levels rebounded from the point of greatest decline with mutations associated with resistance to ritonavir. The second analysis included a cohort of 102 patients who initially responded to randomized treatment with either monotherapy with ritonavir or combination therapy with ritonavir and zidovudine. Methods: Durability of response was defined as the time from the initiation of therapy to the point at which plasma HIV RNA displayed a sustained increase of at least 0.6 log(10) copies/ml from the nadir value. In the first analysis, durability of response was analyzed with respect to baseline HIV RNA, HIV RNA at the nadir, and the drop in HIV RNA from baseline to the nadir. In the second analysis, time to rebound was examined using Kaplan-Meier analysis, stratifying by either baseline HIV RNA or HIV RNA at the nadir. Results: In both analyses, the durability of response was not highly associated with either baseline RNA or the magnitude of RNA decline from baseline. Instead, a strong relationship was observed between the durability of response and the nadir plasma HIV-1 RNA value (P < 0.01). The nadir in viral load was generally reached after 12 weeks of randomized therapy. Conclusions: Viral RNA determinations at intermediate timepoints may be prognostic of impending virologic failure of protease inhibitor therapy. Therapeutic strategies that allow intensification of initial antiretroviral regimens in the subset of patients with incomplete virological response before the emergence of high level resistance should be investigated. (C) 1998 Rapid Science Ltd.
引用
收藏
页码:F9 / F14
页数:6
相关论文
共 50 条
  • [21] HIV-1 RNA quantification in CRF02_ AG HIV-1 infection: too easy to make mistakes
    Tatarelli, Paola
    Taramasso, Lucia
    Di Biagio, Antonio
    Sticchi, Laura
    Nigro, Nicola
    Barresi, Renata
    Viscoli, Claudio
    Bruzzone, Bianca
    NEW MICROBIOLOGICA, 2016, 39 (02) : 150 - 152
  • [22] Gender difference in HIV-1 RNA viral loads
    Donnelly, CA
    Bartley, LM
    Ghani, AC
    Le Fevre, AM
    Kwong, GP
    Cowling, BJ
    van Sighem, AL
    de Wolf, F
    Rode, RA
    Anderson, RM
    HIV MEDICINE, 2005, 6 (03) : 170 - 178
  • [23] Course of viral load throughout HIV-1 infection
    Sabin, CA
    Devereux, H
    Phillips, AN
    Hill, A
    Janossy, G
    Lee, CA
    Loveday, C
    JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2000, 23 (02) : 172 - 177
  • [24] Comparative evaluation of the Artus HIV-1 QS-RGQ assay and the Abbott RealTime HIV-1 assay for the quantification of HIV-1 RNA in plasma
    Garcia-Diaz, Ana
    Labbett, Wendy
    Clewley, Gillian S.
    Guerrero-Ramos, Alvaro
    Geretti, Anna Maria
    JOURNAL OF CLINICAL VIROLOGY, 2013, 57 (01) : 66 - 69
  • [25] Viral loads in dual infection with HIV-1 and cytomegalovirus
    Boriskin, YS
    Sharland, M
    Dalton, R
    duMont, G
    Booth, JC
    ARCHIVES OF DISEASE IN CHILDHOOD, 1999, 80 (02) : 132 - 136
  • [26] HIV-1 IgA specific serum antibodies and disease progression during HIV-1 infection
    Margalith, M
    Levy, E
    Rinaldo, CR
    Detels, R
    Phair, J
    Kaslow, R
    Saah, AJ
    Sarov, B
    JOURNAL OF HUMAN VIROLOGY, 2001, 4 (05) : 269 - 277
  • [27] The relationship between plasma viral load and neuropsychological functioning in HIV-1 infection
    Reger, MA
    Martin, DJ
    Cole, SL
    Strauss, G
    ARCHIVES OF CLINICAL NEUROPSYCHOLOGY, 2005, 20 (02) : 137 - 143
  • [28] Comparative evaluation of the VERSANT® HIV-1 RNA 1.0 kinetic PCR molecular system (kPCR) for the quantification of HIV-1 plasma viral load
    Ruelle, Jean
    Jnaoui, Karima
    Lefevre, Isabelle
    Lamarti, Najet
    Goubau, Patrick
    JOURNAL OF CLINICAL VIROLOGY, 2009, 44 (04) : 297 - 301
  • [29] Next generation sequencing of HIV-1 protease in the PIVOT trial of protease inhibitor monotherapy
    Dunn, David T.
    Stohr, Wolfgang
    Arenas-Pinto, Alejandro
    Tostevin, Anna
    Mbisa, Jean L.
    Paton, Nicholas I.
    JOURNAL OF CLINICAL VIROLOGY, 2018, 101 : 63 - 65
  • [30] Plasma viral RNA assay in HIV-1 group O infection by real-time PCR
    Gueudin, M
    Plantier, JC
    Damond, F
    Roques, P
    Mauclère, P
    Simon, F
    JOURNAL OF VIROLOGICAL METHODS, 2003, 113 (01) : 43 - 49